Opthamology : 1

Infectious Diseases : 6

Autoimmune/Immunology : 5

Cardiovascular : 4

Respiratory : 1

Renal : 2

Endocrine : 2

Metabolic : 2

Oncology : 25

Neurology : 6

Allergy : 5

Obstetrics/Gynecology : 1

Dermatology : 3

Hermatology : 2

Urology : 1

Psychiatry : 2

Atopic Dermatitis (Eczema) : 4

Congestive Heart Failure (CHF) and Cardiomyopathies : 3

Bladder Cancer : 2

Prostate Cancer : 2

Breast Cancer : 2

Multiple Myeloma (MM) : 3

COVID-19 : 3

Uterine (Endometrial) Cancer : 2

Hyperoxaluria : 2

Indolent Non-Hodgkin’s Lymphoma (Including Follicular Lymphoma) – NHL : 2

Key Potential Drug Launches in 2021Take a longer-term look at key late-stage drugs (including vaccines) projected to hit the market in 2021, including new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.

ID : 911138

Source: Biomedtracker, June 2020

Oncology Expected to Have the Largest Number of Key Drugs Launching in 2021

Multiple Launches Expected for Ten Indications, with Atopic Dermatitis Leading

Additional Key Drugs Projected to Hit the Market in 2021 by Lead Company

2021 Potential Launches Include

68 KEY DRUGS62 COMPANIES

56 INDICATIONS

3 DRUGS FOR COVID-19As the pandemic continues, COVID-19 is among the top indications by number of expected launches. With substantial public funding and unprecedented compression of clinical development timelines, 3 vaccines have the potential to gain Emergency Use Authorizations by the end of 2020.

DRUG COMPANY(IES) MODALITY AZD1222 University of Oxford; AstraZeneca Adenoviral vector BNT162 Pfizer; BioNTech; Fosun mRNA mRNA-1273 Moderna mRNA

1ST

2ND

Click Here to Speak Now to a Biomedtracker

Team Member to Find Out More

25 DRUGSare expected to

launch in 2021 for Oncology across

20 different types of cancer

Infectious Disease (ID) and Neurology tie for 2nd place,

each with 6 DRUGS

4 DRUGSexpected for Atopic

Dermatitis (Eczema) are: � Pfizer’s abrocitinib � Eli Lilly’s Olumiant � AbbVie’s Rinvoq � Incyte’s Ruxolitinib

COMPANY DRUG INDICATION(S)

Pfizer Abrocitinib Atopic Dermatitis (Eczema)

PF-06482077 Pneumococcal (Streptococcus pneumoniae) Vaccines (Antibacterial)

TG Therapeutics TG-1303 Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) – NHL

Umbralisib Indolent Non-Hodgkin’s Lymphoma (Including Follicular Lymphoma) – NHL

Marginal Zone Lymphoma – NHL

Roche Etrolizumab Ulcerative Colitis

Ipatasertib Breast Cancer

BioMarin Pharmaceutical

Roctavian Hemophilia A

Vosoritide Achondroplasia

Novartis Lutetium 177Lu-PSMA-617 Prostate Cancer

PDR001 Melanoma

Incyte Corporation Pemazyre Bladder Cancer

Ruxolitinib Cream Atopic Dermatitis (Eczema)

Each vaccine has been shown

to induce neutralizing antibodies

to the SARS-CoV-2 spike protein.

Late stage trials have launched

for all vaccine candidates, each

enrolling up to 30,000 adults

in the US or globally.